AbbVie Stock: Shares Soar 4.24% Amid Acquisition Rumors

Stock Performance Details

AbbVie's stock rose by 4.24% during the session on January 7, closing at $233.42. This increase is part of a favorable trend as the stock has risen by 2.16% over the past week. Over the year, the performance reached 30.02%, significantly outperforming the S&P 500, which stood at 18.33% for the same period. The overall American market showed more modest progress during this session, with the benchmark S&P 500 index gaining 0.36% to reach 6740.28 points. Trading volumes indicated significant market interest, with 10,285,385 shares traded, representing 0.58% of the company's market capitalization. This capital turnover, although less than 1%, reflects sustained activity on the stock during this session.

Potential Acquisition Talks

The Wall Street Journal reported that the laboratory was in advanced talks to acquire Revolution Medicines, a biotechnology company developing cancer drugs. According to these reports, the deal could value the target between $15.4 billion, its market capitalization on January 6, and potentially $20 billion, taking into account a usual acquisition premium. However, AbbVie denied these reports on the same day, stating in a press release that it was not in discussions with Revolution Medicines. The stock subsequently fell by 1% in after-hours trading following this denial. This acquisition project would be part of a broader strategy by the group, which has already spent more than $20 billion on external growth operations since 2023. This approach aims particularly to offset the loss of patent protection for Humira, its flagship treatment for rheumatoid arthritis, which faced competition from biosimilars. Additionally, the group has released its adjusted earnings per share forecast for 2025, ranging from $9.90 to $9.94, according to a document filed with the Securities and Exchange Commission.